B Raf(V600E)
Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series
9
B-Raf and the inhibitors: from bench to bedside
9
B Raf(V600E) and thrombospondin 1 promote thyroid cancer progression
6
Suppression of B-Raf(V600E) cancers by MAPK hyper-activation
11
AurkA inhibitors enhance the effects of B RAF and MEK inhibitors in melanoma treatment
9
Heme oxygenase 1 facilitates cell proliferation via the B-Raf-ERK signaling pathway in melanoma
12
Inactivation of Icmt inhibits transformation by oncogenic K Ras and B Raf
13
AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf & TSC1/TSC2
16
TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B Raf mutational status
8
ERK/pERK expression and B raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics
11
Treatment of B RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
10
Original Article Functional cross-talk between cAMP and ERK1/2 pathway promotes proliferation of somatotropinomas in a B-Raf and C-Raf dependent manner
13
A novel MCF-10A line allowing conditional oncogene expression in 3D culture
13
Clinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical Engineering, Lund University, BMC D13, 221 84 Lund, Sweden
11
Computational Modelling, Synthesis and Biological Evaluation of Guanidinium like Derivatives as Protein Kinase Inhibitors for the Treatment of Cancer
362
B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells
14
Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway
12
Suspension state promotes metastasis of breast cancer cells by up-regulating cyclooxygenase-2
15
Comparative Docking Studies of Osthol Derivatives and Sorafenib on BRAF V599E Mutant Protein
8
The promise of circulating tumor cell analysis in cancer management
10